← Human Trials & Peer-Reviewed Studies
Exenatide Regulates Cerebral Glucose Metabolism in Brain Areas Associated With Glucose Homeostasis and Reward System
Plain-language guide to PMID 26116695 (2015): double-blind randomized controlled trial study of Exenatide in 15 subjects.
Key Facts
- PMID
- 26116695
- Journal
- Diabetes
- Year
- 2015
- Study type
- Randomized Controlled Trial
- Authors
- Daniele G et al. (12 authors)
- DOI
- 10.2337/db14-1718
- Registered trial
- NCT01588418
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Exenatide.
The study aim was to evaluate the effects of a single injection of the GLP-1RA exenatide on cerebral and peripheral glucose metabolism in response to a glucose load.
Why It Was Studied
Glucagon-like peptide 1 receptors (GLP-1Rs) have been found in the brain, but whether GLP-1R agonists (GLP-1RAs) influence brain glucose metabolism is currently unknown.
Who Took Part
The study group was 15 subjects.
The age groups tagged for this paper are middle-aged adults, men only.
How the Study Was Run
In design terms this was a randomized, double-blind, placebo-controlled and crossover study.
The subjects were allocated by chance, so the Exenatide group and the comparison group should start out alike.
Neither the subjects nor the staff measuring them knew who was on Exenatide, so expectations could not easily colour the readings.
The comparison arm used a placebo, so changes seen with Exenatide could be set against what happens without it.
Each person switched between Exenatide and the comparison at some point, usually with a gap in between.
The cerebral glucose metabolic rate (CMRglu) was measured by positron emission tomography after an injection of [(18)F]2-fluoro-2-deoxy-d-glucose before the OGTT, and the rate of glucose absorption (RaO) and disposal was assessed using stable isotope tracers.
What Was Measured
The subject headings attached to it are Blood Glucose, Cerebrum, Diabetes Mellitus, Exenatide, Glucose Tolerance Test, Glycated Hemoglobin and Homeostasis.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Exenatide in 15 subjects.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 2015 (Diabetes), a journal based in United States.
More context: the Exenatide compound page.
Our Notes on the Compound
Exenatide: A 39-amino-acid GLP-1 receptor agonist first identified in Gila monster venom; sold as Byetta and Bydureon for type 2 diabetes.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.